The effects of combining erythromycin (Ery) with oxytetracycline (Oxy) or spectinomycin (Sp) on Pasteurella haemolytica were evaluated in vitro using the chessboard (checkerboard) technique. These combinations were selected because all are drugs widely used in bovine respiratory disease treatment, and they represent possible sequential or complementary mechanisms of action. Using the recommended breakpoints of >4 µg/ ml for Ery, 16 µl for Oxy, and 32 µl for Sp, of the 33 P. haemolytica isolates, 32 were resistant to Oxy, 27 to Sp, and 14 to Ery. Based on the fractional inhibitory concentration index, Ery and Oxy in combination were synergistic or additive against 32 of 33 isolates. The combination of Ery and Sp was synergistic or additive against 27 of 33 isolates. No instances of antagonism were seen. When the effects were considered within the context of therapeutically achievable serum/tissue concentrations, the effects of Ery and Oxy in combination were only marginal. Thus, against P. haemolytica isolates, Ery and Sp appeared to represent an effective antimicrobial combination, whereas Ery and Oxy were only of marginal efficacy as a combination.
Pasteurella haemolytica serotype 1 is a primary cause the 50s ribosomal subunit and inhibits translocation of the bovine respiratory disease complex, a severe of nascent peptides, possibly by enhancing premature fibrinous pneumonia often associated with shipping of dissociation of peptidyl tRNA from ribosomes. 10, 15 Sp cattle . 12, 20 This is a very serious disease of cattle with binds mainly to the 30s ribosomal subunit, inhibiting morbidity and mortality rates of up to 100% and 30%, initiation complexes and translocation in early peptide respectively. A wide variety of antimicrobials are re-bond formation. It is most effective in early transloported to be effective when treatment is initiated with-cations, with some reinitiations occurring later because out delay. l3 More recently, the array of effective anti-it is a reversible inhibitor. 10, 21 Thus, the 3 drugs may microbials for P. haemolytica seems to be decreasing be visualized to effect sequential events in protein synwith a high percentage of isolates now resistant to the thesis or to produce complementary actions to offset penicillins, tetracyclines, and sulfonamides. 9, 17 Pasteureversible effects at a similar site. Because different rella haemolytica isolates that are resistant to the commonly used and FDA-approved antimicrobial drugs binding sites seem to be involved and all are primarily bacteriostatic, the likelihood of antagonism is diminare encountered more frequently, and deaths in some ished. The purpose of this study was to determine the cases are attributable to bacteria resistant to antimicro-effects of erythromycin in combination with Oxy or Sp bials. 12 Because of the seriousness of the disease and on P. haemolytica as compared to these antimicrobials lack of therapeutic response to single drugs in many cases, antibiotic drug combinations are often used. Unfortunately, in most instances there is little information to guide either selection or dosage of the antimicrobial alone.
Materials and methods
combinations for use against P. haemolytica. Bacterial isolates. Thirty-three P. haemolytica serotype 1 The combinations of erythromycin (Ery) and oxy-isolates were obtained from 2 sources: routine specimens tetracycline (Oxy) or spectinomycin (Sp) have a po-from bovine respiratory disease received at the Oklahoma tential in clinical use because of their mechanism of Animal Disease Diagnostic Laboratory, Stillwater, Oklaaction. Oxy binds to the 30s ribosomal subunit mainly, homa, and tracheal swabs from cattle in a commercial feedand reversibly inhibits binding of aminoacyl tRNA to yard." the A site, a step prior to translocation. 10 C prior to use. Quality control of the trays was carried out Received for publication September 3, 1988. by testing periodically using Escherichia coli ATCC 25922 and Staphylococcus aureus ATCC 29213. In addition, the minimal inhibitory concentrations (MIC's) of all the P. haemolytica isolates were compared with results obtained using a commercial d microdilution method.' In all cases the MIC's were within 1 dilution for the 2 methods. $V a final check on reproducibility, the MIC's for Ery were compared between the Ery/Oxy (Table 1) and Ery/Sp (Table 2 ) trays, in which case they were the same for 27 isolates and within 1 dilution for the remaining 6 isolates.
Prior to inoculation, the trays were thawed at room temperature for approximately 1 hr prior to use. Four to 5 wellisolated colonies were inoculated into 0.5 ml of brain heart infusion (BHI) broth and incubated for 3-5 hr at 35-37 C. A 0.2-ml aliquot from the incubated BHI tube was transferred to a tube containing 20 ml of sterile distilled water and carefully mixed by inversion. A 0.002-ml aliquot of this suspension, containing approximately 10 7 colony-forming units (CFU)/ml, was inoculated into each of the 96 wells of the microtitration tray b and incubated for 16 hr at 35-37 C.
The trays were read with the aid of a reflective viewer d using diffused room light. The MIC was recorded as the lowest concentration or concentrations in combination that prevented macroscopically detectable growth.
Antimicrobial activity assessment. Evaluation of the results was carried out directly by comparing the MIC's and effects of each drug on the MIC's of the other and secondarily by using the fractional inhibitory concentration (FIC) technique, calculated as follows: 2, 6 MIC of A MIC of B
FIC index = in combination in combination MIC of A alone + MIC of B alone
An FIC index ≤ 0.5 indicates synergy, > 0.5-l.5 additive effects, 2 indifference, and >2 antagonism. ll
Results
The MIC's for Ery and Oxy alone or in combination are presented in Table 1 while those for Ery and Sp alone or in combination are presented in Table 2 . To facilitate calculation of the FIC index, isolates for which the MIC was greater than the concentration in the last well of the final row were assigned an MIC estimated as the next doubling dilution. Thus for Ery, >4 is 1,2 ). For Oxy the range was 0.5-> 32 µg/ml alone and 0.06,>32 µg/ml in combination with Ery ( Table 1 ). The range for Sp alone was 16-> 32 µg/ml and in combination with Ery was 0.5-32 µg/ml. Comparison using the FIC index indicates that the Ery/Oxy combination was synergistic against 22, additive against 10, and indifferent against 1 of the 33 isolates. The Ery/Sp combination was synergistic against 15, additive against 12, and indifferent against 6 of the 33 isolates.
Discussion
The use of minimal inhibitory concentrations is becoming widely accepted as a guide for antibiotic usage; however, the same concept applied to evaluation of antibiotic combinations is viewed with reservation. l6 Various methods have been used to assess antimicrobial combination efficacy, and while some reports indicate reasonable correlation between the methods, others have shown a poor correlation. 18, 22 One apparent discrepancy lies with the grading of results, especially with the chessboard technique. The major question is: what constitutes synergy -addition or antagonism? The distinction between synergy and additive effects may be mostly of academic interest because in both cases there is a desirable effect on bacteria. Of greater importance is the distinction between additive effects and so-called antagonism. This may have great bearing on the therapeutic use of drug combinations. The term antagonism may be applied inappropriately. When no additive effects are noted with antibiotic combinations, this is sometimes termed antagonism. Because each drug may exert independent effects, many have considered that anything less than the sum of the independent effects is antagonism. Thus, when 2 drugs are used and neither influences the effect of the other for better or worse, the result is often classed as antagonism because they failed to exert their independent effects. This is not true antagonism and is very misleading to the clinician attempting to use the information therapeutically. When the addition of a second drug is without influence on the effect of the first drug, it more logically should be termed indifference. 10 With this definition, very few antibiotic combinations can be shown to be antagonistic.
From the results it can be seen that there is clearly a favorable effect when Ery is combined with either Oxy (Table I) However, when consideration is given to serum or tissue concentrations achievable therapeutically, the results differ. The interpretation of in vitro antimicrobial activity assessment is dependent upon estimations of antimicrobial concentrations at the site of infection in vivo. Thus, breakpoint concentrations are recommended as representative of serum or tissue concentrations attainable with the usual therapeutic dosage. l4 Breakpoints indicate the dividing line between susceptibility and resistance; however, they are not fixed points since they are dependent upon dosage and a host of other factors that influence antimicrobial activity at the site of infection. The P. haemolytica isolates were classified as resistant using recommended general breakpoints 8, 19 of 8 µg/ml (or >4 since 4 was the highest concentration tested) for Ery, 16 µg/ml for Oxy, and 32 µg/ml for Sp. For the purposes of our discussion, antimicrobial concentrations attainable in cattle with typical dosages were used to modify the breakpoints. Therefore, the following possible serum/tissue concentrations were considered: 2 µg/ml reasonable and 4 µg/ ml possible for Ery 4 and Oxy 5 and 16 µg/ml reasonable for SP. 20 One should consider, however, that serum/ tissue concentrations in excess of the MIC may be necessary'; thus, the lower breakpoints may be more representative.
Setting the concentration criteria at 2 µg/ml Ery and 2 µg/ml Oxy, there is 1 isolate exhibiting synergism and 1 with additive effects, excluding those sensitive to 2 µg/ml Ery alone. Increasing the criteria 2 µg/ml Ery and 4 µg/ml Oxy gives the same results. When the criteria are raised to 4 µg/ml Ery and 4 µg/ml Oxy (a marginal situation as regards likelihood of achieving these serum/tissue concentrations), 17 out of 19 isolates with an MIC of greater than 4 µg/ml for Ery responded, with synergy in 15 and additive effects in 2. In comparison, with 2 µg/ml Ery and 8 µg/ml Sp (readily achievable concentrations in serum/tissue), 3 isolates exhibit synergism and 6 additive effects, excluding the 3 isolates sensitive to 2 µg/ml Ery alone. Increasing the criteria to 2 µg/ml Ery and 16 µg/ml Sp results in an additional 12 isolates with synergy. At 4 µg/ml Ery and 16 µg/ml Sp, all 14 isolates with an MIC >4 µg/ml for Ery responded, with synergy in 12 and additive effects in 2.
The data may also be compared by examining the concentrations of Oxy and Sp required to augment the effects of Ery. Although the use of MIC means may be subject to distortion, it may more readily allow conceptualization of the dosages needed to provide the appropriate serum or tissue concentrations. For those isolates with an MIC for Ery (resistant) >4 µg/ml a combination of 4 µg/ml Ery and a mean of 4.3 µg/ml Oxy or 5.0 µg/ml Sp was required to inhibit growth. For those isolates with an MIC ≥2 µg/ml for Ery, a combination of 2 µg/ml Ery and a mean of 23.2 µg/ ml Oxy or 18.6 µg/ml Sp was required to inhibit growth. The 4.3 µg/ml Oxy is difficult to attain except with intravenous administration, whereas 23.2 µg/ml Oxy is clearly well beyond attainable concentrations in serum/tissue with reasonable dosage. The 5.0 µg/ml Sp is readily attainable in serum/tissue even with low dosage, and 18.6 µg/ml Sp is reasonable when high dosages are used.
Thus on the basis of in vitro testing, the combination of Ery and Sp appears to be more effective in inhibiting P. haemolytica isolates than either drug used alone at concentrations attainable therapeutically. The combination of Ery and Oxy, while exhibiting favorable effects, was only marginally effective at concentrations achievable therapeutically at reasonable dosages. However, these results should be considered in light of the sensitivity of the P. haemolytica isolates to the respective drugs. All but 1 of the 33 isolates were resistant to Oxy, 14 to Ery, and 27 to Sp. Isolates less resistant to Oxy may have shown a favorable response to the Ery and Oxy combination at more reasonable Oxy concentrations. These beneficial effects may be attributable to sequential mechanisms of action or to individual activities against strains resistant to the accompanying drug. Regardless of whether the combination effects are synergistic or additive, the dosages in combination should not be reduced from those used with each drug alone. In some cases with these particular isolates, the dosages required would be higher than those normally recommended for Ery or Oxy. This should not be a serious limitation because these drugs are of relatively low toxicity potential. However, a longer withholding period may be required with increased dosage.
